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Abstract
Atherosclerosis and malignancy are pervasive pathological conditions that account for the
bulk of morbidity and mortality in developed countries. Our current understanding of the
patholobiology of these fundamental disorders suggests that inflammatory processes may
differentially affect them; thus, atherosclerosis can be largely driven by inflammation, where
as cancer often flourishes as inflammatory responses are modulated. A corollary of this hy-
pothesis is that cancer (or its treatment may significantly attenuate atherosclerotic disease
by diminishing host inflammatory response, suggesting potential therapeutic approaches.
To evaluate the relationship between cancer and cardiovascular atherosclerotic disease,
we assessed 1,024 autopsy reports from Brigham andWomen’s Hospital and performed
correlative analyses on atherosclerotic severity and cancer prevalence. In gender- and age-
matched populations, there is a statistically significant inverse correlation between history
of malignancy and autopsy-proven atherosclerotic disease. In a second analysis, we evalu-
ated 147,779 patients through analysis of the Harvard Catalyst SHRINE database and dem-
onstrated a reduced non-coronary atherosclerotic disease rate: control (27.40%), leukemia/
lymphoma (12.57%), lung (17.63%), colorectal (18.17%), breast (9.79%), uterus/cervix
(11.47%), and prostate (18.40%). We herein report that, based on two separate medical
records analysis, an inverse correlation between cancer and atherosclerosis. Furthermore,
this correlation is not uniformly associated with anti-neoplastic treatment, suggesting that
the inverse relationship may be in part attributable to an individual’s intrinsic inflammatory
propensity, and/or to inflammation-modulatory properties of neoplasms.
Introduction
Atherosclerosis is an inflammation driven disease characterized by arterial wall thickening as-
sociated with local hyperplastic growth and accompanied by immune cell infiltration and
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accumulation of lipids. Linked to events such as myocardial infarction and stroke, it is consid-
ered the causative factor for most cardiovascular diseases (CVD) and a leading candidate for
worldwide mortality with roughly 13.5 million associated deaths in 2008 [1].
Several modes of interventional therapies are commonly practiced towards combating this
highly pervasive disease: lifestyle changes (diet and exercise), pharmaceutical agents, and inva-
sive vascular surgeries in the most severe cases [2]. These therapies are generally thought to be
associated with improved cardiovascular risks, however, a complete understanding of their
mechanisms of actions as well as inherent underlying pathological development is still lacking
[3,4,5]. Recent years have demonstrated that aggressively lowering lipid levels does not have as
profound an effect as once believed while the efficacious nature of statins now appears to stem
from their anti-inflammatory properties; both these notions begin to challenge the long held
belief that lipid control and attenuation would be the predominant path towards atherosclerot-
ic improvement [5–11]. This has been further substantiated with the use of C-Reactive Protein
(CRP), a marker of global inflammation, as a better diagnostic tool than lipid levels [12]. The
World Health Organization (WHO) estimates an increase to nearly 24 million CVD associated
deaths by 2030 [1]. New molecular pathways and mechanisms must be uncovered in order to
recognize the critical underpinnings of atherosclerotic development and progression.
Malignant cancers are considered a diverse category of diseases and encompass etiologies
ranging from genetic predispositions, exposure to environmental factors, and adverse re-
sponses to inflammation. Direct associations between cancer and causative factors, such as
prolonged estrogen exposure in estrogen-receptor positive breast carcinomas, exist but, unfor-
tunately, it is not possible to state a “unifying” theory for the pathological origin of cancer. Al-
though cancer is a leading cause of morbidity and mortality, immune surveillance provides a
crucial control mechanism in keeping malignant incidences at some minimum. Hematological
malignancies, including lymphomas and leukemias, are comprised of aberrant cells that nor-
mally initiate and control the inflammatory response—this may explain a greater effect in
these cancers on atherosclerosis as herein reported. Immunosuppression, whether congenital,
acquired, or iatrogenic, also produces malignancies in these populations more frequently than
in normal hosts.
We propose that the baseline human physiology can be either pro-, balanced, or anti-in-
flammatory; and/or that neoplastic populations also possess pan-inflammatory characteristics
(more importantly, key anti-inflammatory traits). The patients may exhibit secreted factors or
indirect immune modulatory processes that provide the systemic anti-inflammatory traits. As
a logical extension, we suggest that atherosclerosis results, as data suggests, from pro-inflam-
matory individuals and, at the other end of the spectrum, anti-inflammatory individuals could
have a higher predilection for cancers.
This hypothesized inverse relationship between atherosclerosis and malignancy builds off of
anecdotal pathological observations as well as sparse reports in literature from more than half a
century ago. Several reports dating back to the 1950s noted decreased atherosclerotic burden
through autopsy analyses [13,14,15]. Though this phenomenon was documented, no substan-
tial effort was made towards establishing a concrete mechanism of action. Further, the com-
mon presumption that “chemotherapy removes atherosclerosis” is dated, unsubstantiated, and
not rational within the current understanding of atherosclerotic biology.
We evaluated data from Brigham and Women’s electronic medical records database and the
Harvard Catalyst Shared Health Research Information Network (SHRINE) to assess the severi-
ty and prevalence of atherosclerotic disease as a function of cancer history and status.
Atherosclerosis vs. Cancer in Humans
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Methods
Ethics statement
The institutional review board of the Brigham andWomen’s Hospital reviewed and approved
this study. All data were analyzed either in de-identified format or were from deceased patients
(over a 10 year period) in whom written informed consent was not feasible.
Autopsy dataset
The autopsy data set was chosen as a time point analysis for the history or current status of ma-
lignancy and definitively and completely defined atherosclerotic disease of all sites. This al-
lowed for the assessment of two specific disease types regardless of the etiology of death. Final
autopsy reports were obtained through the Brigham andWomen’s Hospital Longitudinal Med-
ical Records (BWH-LMR) database. Reports were manually analyzed from 2004–2012 for the
following patient information: age, gender, history of cancer (yes/no), cancer type (if applica-
ble), history of smoking (yes/no), hypertension (yes/no), type I/II diabetes mellitus (yes/no),
aortic atherosclerosis (graded by severity), and coronary atherosclerosis (graded by severity).
The qualitative reports by pathologists of atherosclerosis status in autopsy cases were nor-
malized and assigned a numerical severity grading. The grading scale consisted of 5 tiers: none,
minimal, mild, moderate, and severe. Characteristics that were commonly assessed within re-
ports consisted of percent vessel occlusion, severity of calcification, ulcerative status, and de-
scriptive statements of “minimal”, “severe”, etc.
Exclusion criteria for reports included: only neurologic reports provided, no reported ath-
erosclerosis status of aortic and coronaries, or patients having a history of more than one
cancer.
Imputation
Numerous reports indicated either aortic or coronary atherosclerosis in autopsy records. Al-
though there can be discordance between aortic and coronary atherosclerotic disease, for pur-
poses of statistical calculations, we made an assumption that atherosclerotic disease in the
aorta and coronaries likely progress on a similar time and severity scale. Unreported athero-
sclerosis statuses of either the coronaries or the aorta were thus imputed to prevent loss of the
data point. The missing information was assigned the same grading value as the one that was
actually reported. The fallacy in such imputation is regression towards the mean of effect size
evaluated. The validity of this imputation was confirmed by comparing the pre- and post-im-
putation effects on the model outputs (S1 and S2 Tables).
Medical Records Cohort Dataset
Cohort information was obtained through the Harvard Catalyst Shared Health Research Infor-
mation Network (SHRINE)—a web-based query tool capable of determining the aggregate
number of patients at participating hospitals that meet a given set of inclusion/exclusion crite-
ria. Our dataset was limited to a patient population over 50 years of age to avoid genetic muta-
tions that lead to premature atherosclerotic and/or cancer syndromes. The dataset was further
simplified to assess non-coronary associated atherosclerosis (cerebrovascular disease, aortic
and peripheral arterial embolism or thrombosis, aortic, peripheral, and visceral artery aneu-
rysms, and peripheral and visceral atherosclerosis). A total of 147,779 patients were available
for analysis.
An out-group (patients with non-pathological fractures) was selected as a proxy for “popu-
lation” prevalence of atherosclerosis; this was validated against a published rate for
Atherosclerosis vs. Cancer in Humans
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atherosclerosis. A broad test group panel of cancers was selected: male cancer (prostate), sex in-
dependent cancer (lung and colon), female cancers (breast, uterus/cervix), and leukemia/lym-
phomas. Analyses were performed through dual reciprocal searches. For a given category (i.e.
lymphoma), we queried the complete dataset for those with lymphoma and non-coronary as-
sociated atherosclerosis and divided by those with lymphoma only, producing a percentage.
The reciprocal search was performed on those with non-coronary associated atherosclerosis
with lymphoma over the total.
Statistical Analysis
All statistical analyses were performed through STATA Data Analysis and Statistical Software
(StataCorp LP). Multivariate logistic regressions employed a jackknifing resampling technique
in order to assess biases within the dataset. All regressions outputs are shown in S3 Table. The
outcome variable was cancer being tested for association with aortic/coronary atherosclerosis.
The covariates for the models were age, gender, history of smoking, hypertension, and diabetes.
All models were initially regressed using the entirety of the aforementioned parameters. P-val-
ues for all variables and intermediate model states are shown in supporting information (S1,
S2, and S3 Tables). Pseudo-r2 values for the model were computed. Model parameters were
then further optimized on a per cancer subset basis as follows: the gender variable was not in-
cluded in gender specific cancers; parameters were considered essential if removal resulted in a
greater than 10% change in odds ratio or a greater than 5% increase in standard error.
Aortic and coronary atherosclerosis were assessed in separate models. Simple imputa-
tion was used to generate missing data, for aortic and coronary, to maximize the number of
valid cases in the model. Imputation proceeded as follows: when data was available for aortic
but not coronary, the aortic data was assigned to coronary; when coronary data was available
but not aortic, coronary data was assigned to aortic; if both were missing, the case was exclud-
ed. The natural biological correlation of aortic and coronary atherosclerosis is variable, howev-
er, only 197 cases had values imputed in either direction (19%) and 58 cases were excluded
(6%). The two outputs were highly correlated and, thus, only one was used per model as to not
over fit the data.
Categorical analyses were performed on the following cancer groups: cancer, carcinoma, he-
matologic, sarcoma, neurologic, lung, breast, prostate, leukemia, lymphoma, and myeloma. Se-
lection and subdivision into more specific cancers classes was dictated by sample number in
which a minimum of n = 20 was set.
Within the SHRINE data, binomial proportion was used to assess the significance of differ-
ences in the cancer groups vs. the outgroup (fractures).
Results
Autopsy Results
Characteristics of the autopsy dataset are summarized in Table 1. A total of 1,024 final autopsy
reports from Brigham andWomen’s Hospital between 2004–2012 were analyzed, 502
(49.02%) were free of any cancer history while 522 (50.98%) had some history of cancer. There
was a wide range of cancer subtypes, age, and prevalence of risk factors for atherosclerosis.
The coronary artery disease score and the aortic atherosclerosis score showed modest agree-
ment in the raw data set (42.39%) with Pearson correlation of 0.5864. After imputation, the
agreement remained modest (53.94%) with identical correlation (0.5864). The correlation of
the pre- and post-imputation scores for each category were 0.9997 (coronary artery disease)
and 0.9996 (aortic atherosclerosis). In supporting information, we show the detailed OR for
cancer and subtypes for both aortic and coronary atherosclerosis before and after imputation
Atherosclerosis vs. Cancer in Humans
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for which the ORs largely agree except as follows: Lung for aortic could not be calculated but
was resulted after imputation and increased slightly for coronary; heme (grouped), neuro, and
sarcoma cross 1.0 after imputation suggesting these results in a coronary model are not associ-
ated (but all held true in aortic) (S1 and S2 Tables).
Significant, negative correlations were noted between presence of cancer and atherosclerosis
severity when controlled for standard population characteristics and atherosclerotic risk fac-
tors. The complete cancer group had an odds ratio of 0.468 (95% CI: 0.287–0.765) for aortic
atherosclerosis and 0.772 (95% CI: 0.518–1.151) for coronary atherosclerosis. Comparatively,
hematologic cancers (OR 0.478, 95% CI: 0.261–0.874), carcinoma (OR 0.566, 95% CI: 0.293–
1.070), sarcoma (OR 0.561, 95% 0.112–2.799), and neurologic cancers (OR 0.301, 95% CI:
0.112–2.799) had similar effects on aortic atherosclerosis, Table 2. There appeared greater dis-
parity in coronary atherosclerosis: hematologic (OR 1.047, 95% CI: 0.604–1.814), carcinoma
(OR 0.596, 95% CI: 0.370–0.960), sarcoma (OR 0.869, 95% CI: 0.230–3.286), and neurologic
(OR 1.182, 95% CI: 0.361–3.873), Table 3. Further sub-categorical analyses can be found in
both Tables 2 and 3. Pseudo-r2 (ρ2) values for each model are shown in supporting information
tables but ranged from 0.12 to 0.32 depending on the model (S1, S2, and S3 Tables). It should
be mentioned that pseudo-r2 interpretations are quite different from standard r2 analyses. Val-
ues from 0.2–0.4 are said to have excellent fit characteristics where the ~0.15 range is fair [16].
There appears to be a heterogeneous, correlative spread between atherosclerosis severity
(with variance between aortic and coronary) and specific subgroups of cancers. Though this
may be resultant of underlying/associative factors aside from the cancers themselves, we believe
that this is not the case, and the differences are inherently tied to the cancer types themselves.
Table 1. Descriptive population statistics.
Cancer No Cancer
Female Male Female Male
# of Individuals 210 312 218 284
Age Range
<20 0 1 0 1
20–39 11 24 19 23
40–59 83 111 59 110
60–79 95 146 105 118
80+ 21 30 35 32
Smoking History
Unknown 121 180 127 171
No 55 65 41 39
Yes 34 67 50 74
Hypertension
No 114 151 66 88
Yes 96 161 152 196
Diabetes Mellitus
No 185 256 148 183
Yes 25 56 70 101
A total of 1,024 patient ﬁles were assessed over an eight-year time frame. Information on gender, age, history of smoking, hypertension, and diabetes
were assessed along side atherosclerotic burden and cancer in our multivariate analysis.
doi:10.1371/journal.pone.0126855.t001
Atherosclerosis vs. Cancer in Humans
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SHRINE Results
Larger, multi-hospital cohort analysis revealed a significantly lower incidence of diagnosed ath-
erosclerotic related conditions when compared to the control group (non-pathological frac-
tures); the dataset is summarized in Table 4. This dataset was composed of a smaller subset of
cancer types; these cancers were informed by our autopsy results and represented a spread be-
tween genders and the more clinically prevalent neoplasms. All prevalence rates for all cancer
types when compared with the fracture group were highly significant (p-value<0.0001).
Patients in the fractures control group exhibited a diagnosed, non-coronary atherosclerotic
disease rate of 27.40%. This value is nearly double all cancer groups that were tested; leukemia/
lymphoma (12.57%), lung (17.63%), colorectal (18.17%), breast (9.79%), uterus/cervix
(11.47%), and prostate (18.40%). Overall, there is a decreased incidence in all cancers as
Table 2. Aortic atherosclerosis, statistical results.
Odds Ratio Std Error P CI ρ2 n
Cancer 0.468 0.117 0.002 0.287–0.765 0.2309 522
Carcinoma 0.566 0.184 0.080 0.293–1.070 0.2310 259
Breast 0.329 0.218 0.095 0.084–1.218 0.2840 23
Prostate* . . . . 0.2683 22
Lung 1.801 1.90 0.577 0.228–14.213 0.2585 50
Heme 0.478 0.148 0.017 0.261–0.874 0.2417 177
Leukemia 0.434 0.157 0.021 0.213–0.884 0.2417 90
Lymphoma 0.729 0.351 0.511 0.283–1.873 0.2679 65
Multiple Myloma 0.135 0.083 0.001 0.126–1.238 0.2803 22
Neuro 0.301 0.170 0.033 0.100–0.090 0.2818 25
Sarcoma 0.561 0.460 0.481 0.112–2.799 0.2624 22
A multivariate jackknife analysis method was employed using STATA Data Analysis and Statistical Software. N = 20 was the minimum number of samples
set for analysis. ρ2 is known as pseudo R2. Note that the n column is not cumulative as "carcinoma" includes breast, prostate, and lung.
* Logistic regression sub-analysis was prostate was not possible; likely stemming from insufﬁcient data.
doi:10.1371/journal.pone.0126855.t002
Table 3. Coronary atherosclerosis, statistical results.
Odds Ratio Std Error P CI ρ2 n
Cancer 0.772 0.157 0.204 0.518–1.151 0.1286 522
Carcinoma 0.596 0.145 0.033 0.370–0.960 0.1435 259
Breast 0.378 0.211 0.082 0.127–1.131 0.1946 23
Prostate 0.893 0.953 0.916 0.110–7.224 0.1699 22
Lung 2.165 1.639 0.307 0.491–9.544 0.1787 50
Heme 1.047 0.294 0.871 0.604–1.814 0.1586 177
Leukemia 0.763 0.259 0.425 0.392–1.483 0.2417 90
Lymphoma 3.429 1.98 0.033 1.106–10.632 0.1577 65
Multiple Myeloma 0.395 0.230 0.111 0.126–1.238 0.1886 22
Neuro 1.182 0.716 0.783 0.361–3.873 0.1869 25
Sarcoma 0.869 0.590 0.836 0.230–3.286 0.1733 22
A multivariate jackknife analysis method was employed using STATA Data Analysis and Statistical Software. N = 20 was the minimum number of samples
set for analysis. ρ2 is known as pseudo R2. Note that the n column is not cumulative as "carcinoma" includes breast, prostate, and lung.
doi:10.1371/journal.pone.0126855.t003
Atherosclerosis vs. Cancer in Humans
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expected based on our autopsy results, however, we once again see a disparity between the re-
ported values that likely stem from the differences between the cancers themselves.
Discussion
It is apparent from our study that there exists an inverse relationship between cancer and ath-
erosclerosis. Utilizing two sources of electronic medical records, we found that on a broad
scale, patients of cancer are less likely to be clinically diagnosed for cardiovascular diseases
while post-mortem analysis indicates that the severity of any present atherosclerotic disease is
significantly diminished in such patients. We believe that the anti-inflammatory aspect of can-
cer’s pan-inflammatory response plays an important role towards atherosclerotic attenuation.
Alternatively, the hypothesis of natural pro- versus anti-inflammatory physiology in an indi-
vidual patient is supported by this data.
The seemingly forgotten notion that aspects of cancer may possess the ability to attenuate
atherosclerosis provides a unique approach towards filling this gap in our knowledge between
biology, pathology, and eventually novel therapies [13,14,15]. Likely stemming from the innate
complexities and non-obvious associations between cancer and atherosclerosis, there is a dis-
tinct lack of knowledge regarding their influences on one another. Arguably, there are numer-
ous factors clouding a clear path to causality. For instance, treatment and symptoms of cancer
such as chemotherapy and cachexia have demonstrated the ability to reverse atherosclerosis
[17–20]. Such effects, however, are not completely straightforward; reports have shown that
certain chemotherapeutics can promote atherosclerosis, while the inflammatory nature of ca-
chexia and wasting has been shown to aggravate lesion development [21,22]. Contrasting these
thoughts, we believe that the underlying mechanism lies in possibly innate variations in human
physiology or the direct effect of cancer biology—rather than in the treatments or symptomatic
manifestations.
The correlation between coronary artery disease and atherosclerotic disease of the aorta was
modest in our data set (0.5864), which reflects the known biological observation that patients
may have a severe form of either with no relation to the other. Thus, patients with severe coro-
nary artery disease leading to myocardial infarctions may have relatively clean aortic walls. To
avoid loss of patients in our autopsy dataset, we imputed the aortic and coronary artery athero-
sclerosis scores from each other in a small number of cases. In doing so, the correlation in the
data set remained the same (0.5864) and comparison of the pre- and post-imputation ORs for
a given comparison showed little change except as noted above. This confirms that, despite the
Table 4. Atherosclerotic prevalence in leukemia/lymphoma, lung, colorectal, breast, uterus/cervix, prostate cancer patients and control group:
fractures; patients 50 years old.
Subgroup Prevalence (%) Within Total Athero Prevalence (%) of Athero Within Total Subgroup
Both Leukemia/Lymphoma 4.44 12.57
Lung 5.35 17.63
Colorectal* 5.54 18.17
Female Breast 5.57 9.79
Uterus/Cervix 1.41 11.47
Male Prostate 5.86 18.40
Out group Fractures 9.54 27.40
Prevalence (%) within total athero = (# of patients with speciﬁc cancer and athero) / (total # of patients with athero) * 100. Prevalence (%) of athero within
total subgroup = (# of patient with speciﬁc cancer and athero) / (total # of patients with speciﬁc cancer) * 100.
* The colorectal data from BIDMC produced a fatal error in the union set search and was, therefore, excluded.
doi:10.1371/journal.pone.0126855.t004
Atherosclerosis vs. Cancer in Humans
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use of imputation, the data set we analyzed is essentially the same as the raw data set for the
purposes of the associations we are comparing.
Several of the results with respect to our study are likely to be explained by presently known
biology. Interestingly, our SHRINE results show that the fractures out-group had an athero-
sclerotic rate of 27.4%, which was incidentally very similar to reported values in our selected
age group; this external validation adds confidence to our findings [23]. Our SHRINE dataset
showed that prostate, lung, and colon cancer demonstrated essentially equivalent rates of ath-
erosclerosis, 17.6–18.4%, which are less than fractures. We suspect that our anti-inflammatory
hypothesis plays a role in these patients. We see that in our autopsy analysis, however, lung
cancer has significantly elevated odds ratios, 1.801 in aortic and 2.165 in coronary atherosclero-
sis. We note the following may lead to the witnessed discrepancies and increased rate of athero-
sclerosis: a) lung cancer is strongly associated with smoking which aggravates atherosclerosis,
b) instances of colon cancer are linked with a high fat diet which is also known to accentuate
atherosclerosis [24,25].
Prostate cancer does not exhibit as pronounced an effect on atherosclerosis as other cancers.
This may be due to that fact that prostate cancer is typically a disease of age and will thus have
more overlap with similar temporally related diseases such as atherosclerosis. It should also be
noted that our model could not produce an odds ratio association in our sub-analysis for aortic
atherosclerosis due to low sample numbers. A larger sample set for this specific cancer is need-
ed to address this issue. We confirmed that the inability to produce an odds ratio value was not
due to co-linearity. Regression analysis between aortic atherosclerosis and prostate cancer val-
ues produced an R2 value of 0.01.
A reduced incidence of atherosclerotic disease and severity in breast and uterine/cervical
cancer, seen in both autopsy and SHRINE analyses, comes as little surprise. Estrogen is known
to be protective of atherosclerosis [26,27]. Estrogen likely explains the lower incidences of car-
diovascular disease in women versus men. Cancers of the breast and uterus/cervix may result
in an increased production of cellular derived estrogen resulting in an anti-atherosclerotic
environment.
Results from the hematologic neoplasms proved to be the most unexpected and interesting.
Autopsy analysis revealed odds ratios for aortic and coronary atherosclerosis of 0.434, 0.729,
0.135 and 0.763, 3.429, and 0.395 for leukemias, lymphomas, and multiple myeloma respective-
ly. SHRINE data showed an incidence rate or 12.6%, which is less than prostate and sex-inde-
pendent cancers and at a similar rate compared to female cancers.
There has yet to be a fully substantiated mechanism of action proposed for this phenome-
non. We hypothesize that, due to cellular nature of these hematopoietic malignancies, an anti-
inflammatory environment is promoted or perhaps existed in these patient’s baseline physiolo-
gy, inherently leading to the reduction of any present atherosclerotic burden. What is unclear
about this notion is whether released cytokines directly affect plaques or whether an indirect
immune-modulation relationship is established eventually leading to an anti-atherosclerotic
environment. For instance, it has been shown that regulatory T-cells are prevalent in acute my-
elogenous leukemia (AML) as a means for immune surveillance evasion [28]. It has also been
demonstrated that regulatory T cells posses the ability to attenuate atherosclerosis [29, 30].
Thus, the increased regulatory T-cell recruitment may be one mechanism by which an anti-in-
flammatory physiology is obtained.
A rapidly expanding field, cancer immunology may provide illuminating insight into the
herein reported phenomenon. A hallmark feature of cancer is its ability to evade the host im-
mune system. This allows for unabated tumor expansion and increased potential for metasta-
sis. It is reported that cancer is able to accomplish this feat through numerous mechanisms:
downregulation of surface antigen presenting proteins, cytokine secretion, and reorganization
Atherosclerosis vs. Cancer in Humans
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of the local stromal environment. The predominant mechanism of action is thought to be re-
sultant from cytokine production [31].
These cytokines are suggested to have broad reaching, immune-modulatory effects that
have implications in atherogenesis. TGF-β and IL-10, for example, are two pleiotropic factors
released by numerous cancers that have generalized anti-inflammatory properties. These two
factors can act as T-cell and macrophage suppressors (cells able to eliminate cancer) while also
promoting the development of regulatory T-cells (cells able to prevent tumor specific immune
responses), as mentioned previously. There is concordant evidence that shifts in these particu-
lar immune populations are able to control atherosclerotic lesion development [28–34]. It
should also be noted that cancer cells are well known to secrete pro-inflammatory cytokines
such as TNF-α, IL-6, and IL-1β; all of which act to promote a local, pro-neoplastic environment
(which may also influence atherosclerosis) [35]. It is still unknown whether these are the actual
mechanism by which cancer is capable of modulating atherosclerosis, however, the pro/anti-in-
flammatory balance and immunological linkages between these two disease speaks to the feasi-
bility of the notion.
Further studies have demonstrated that secreted factors from primary tumors and cancer
cell lines are able to regulate T-cell associated inflammation. Several distinct cancer types inter-
fere with NF-κB signaling, prompting anti-inflammatory activity. One study demonstrated
that supernatant derived from AML cells inhibit T-cell nuclear translocation of NF-κB with as-
sociated reductions in IL-2 and IFN-y production [36]. A similar reduction in NF-κB translo-
cation was seen in renal cell carcinomas [37]. NF-κB is a known regulator of atherosclerotic
cytokines such as IL-6, TNF-α, and IL-1β. Thus, NF-κB modification may be a potential mech-
anism by which lesion attenuation is achieved via a diminishment in pro-atherosclerotic cyto-
kines. It would be of interested to investigate whether similar effects were achieved in other
prominent cells found in atherosclerotic lesions such as monocytes and macrophages.
There were several issues with respect to our study that we were unable to fully resolve. One
such factor was the temporal component of patients’ cancer burdens; this is clearly an issue ex-
perienced by the clinical cancer field as a whole. Our hypothesis revolves around the notion
that cancer arises from and promotes a global anti-inflammatory physiology. We postulate that
those with longer courses of cancer burden are likely to have an extensive molecular, anti-in-
flammatory signature with associated reduced atherosclerotic burden compared to those with
shorter cancer courses. Presently, determining the exact timeframe of cancer in humans is not
possible on a clinical scale. Any further experimentation on this phenomenon will likely be
most fruitful in vivo where cancer induction and tracking can be rigorously controlled and
monitored.
Another clinical aspect we were unable to fully resolve was chemotherapy. We did not ex-
clude/include patients based on surgical cure, presence/absence of chemotherapy, or palliative
care only status. Thus, our sampling represents the full spectrum of whatever effect chemother-
apy may have on atherosclerosis. With the numerous forms of chemotherapy compounded
with various treatment durations, inclusion and analysis proved to be intangible. Given that
such treatments are historically aimed towards rapidly dividing cells, unlike resident athero-
sclerotic foam cells, it does not seem likely that diminished atherosclerosis rates in this study in
the timescale of treatment for cancer is due to chemotherapeutics. Furthermore, reversibility in
the dynamics of atherosclerotic disease occurs in early lesions and at the coronary level but has
not been demonstrated in large complex plaque lesions [38–40].
The discrepancies between aortic and coronary atherosclerosis also presented an interesting
result. The locational differences clearly result in drastic pathology spanning myocardial infarc-
tion to stroke. Although the effect of soluble cancer factors may systemic, such observed differ-
ences may be due to the underlying variations in hemodynamics. Because the autopsy data was
Atherosclerosis vs. Cancer in Humans
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incomplete and, thus, imputation was used for statistical purposes, we cannot fully evaluate the
specific relationships between coronary or aortic atherosclerosis independently in our data set.
The herein results represents one of the only recent reports that addresses the inverse rela-
tionship between cancer and atherosclerosis. More exhaustive studies are clearly necessary in
order to truly understand the mechanisms behind this phenomenon. We believe that this novel
paradigm will uncover novel biology towards a greater understanding, and eventually treat-
ment, of atherosclerotic disease.
Supporting Information
S1 Table. The primary outputs are shown for all cancers in the multivariate models includ-
ing aortic or coronary are shown for non-imputed (raw) data by each diagnosis type with a
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